🔥Telegram İfşa

Happy Passover! Happy Hanuman Jayanti! #pathart

Happy Memorial Day!

Just out: International Myeloma Working Group guidelines CAR-T cell treatment in myeloma. For Limited time: Link to Free copy & more in thread! The Lancet Oncology Yi Lin Tom Martin Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Chng Wee Joo Luciano J Costa Ben Derman marivi mateos Joseph Mikhael et al thelancet.com/journals/lanon…

Today marks the 140th anniversary of Memorial Sloan Kettering Cancer Center founding in 1884 as the New York Cancer Hospital! It was renamed, Memorial Hospital for the Treatment of Cancer and Allied Diseases in 1916. NYC is joining the celebration and Empire State Building is lit tonight in MSK blue!

Happy 4th of July!

Remember when we used to avoid mismatched unrelated donor transplants for fear of worse GVHD and NRM outcomes? Those days are over. Congrats to the study team!! 🎉CIBMTR NMDP Brian Shaffer Mahasweta Gooptu Javier Bolaños Meade, MD Steve Spellman Antonio Jimenez Jimenez Monzr M. AlMalki, MD #PTCyrules

Our work with Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 and David Chung at Memorial Sloan Kettering Cancer Center looking at antigen escape with BCMA-targeting therapies in #MMSM patients is now out in @BloodJournal authors.elsevier.com/a/1jUXn1UYwnDBZ 1/7

FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma. fda.gov/drugs/resource… #OCENewsBurst

A total cost of care was compared for letermovir prophylaxis versus preemptive therapy. For high-risk pts, letermovir decreases total cost of care through day+180 and for standard-risk pts, letermovir reduces inpatient cost of care through day+180. astctjournal.org/article/S2666-…

TCT Community, mark your calendars for one of the most unique conferences of the year. Insightful, practical, & forward-thinking topics focused on improving the tolerability (on all levels) of our therapies astct.org/Meetings/Toxic… ASTCT MSK Department of Medicine MSKHemOncTrials

Happy Ganesh Chaturthi!

Colesevelam is highly effective and safe for treatment of lenalidomide associated diarrhea: - Phase 2 trial, 25 pts - 88% improved diarrhea - 68% complete resolution - No effect on lenalidomide PK #mmsm Memorial Sloan Kettering Cancer Center MSKHemOncTrials Blood Cancer Journal rdcu.be/dUqBq

Happy Dussehra!

Effective cytoreduction in the bridging period can significantly improve outcomes for those planned for CAR T cells - radiotherapy ☢️ is a particularly effective tool for highest risk pts! Clinical Cancer Research Memorial Sloan Kettering Radiation Oncology Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx Memorial Sloan Kettering Cancer Center ILROG Team pubmed.ncbi.nlm.nih.gov/39259292/

Happy Diwali! Happy Halloween!

Merry Christmas and Happy Hanukkah !

New research from Memorial Sloan Kettering Cancer Center takes a step toward off-the-shelf CAR T cell therapy for #cancer. Author Karlo Perica explains his and Michel Sadelain's recent study in nature that demonstrated cells from healthy donors can be stored for future use. bit.ly/40W306e

🚨 Just out Nature Medicine! Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive of #CART failure in #lymphoma Led by Sandeep Raj (Sandeep Raj) 👏Memorial Sloan Kettering Cancer Center nature.com/articles/s4159… 🧵Let’s break it down

This is re(n)ally awesome!!! Well-written guidelines re: kidney transplant in myeloma et al by tour de force team: Vaishali Sanchorawala Heather Landau #nelsonleung et al. Nice figures for #MMsm (stratify by 🐠 & MRD), MGUS, and SMM below. 🚨 MRD-neg *not* needed if standard risk.